Literature DB >> 1319700

Visceral leishmaniasis in the BALB/c mouse: antimony tissue disposition and parasite suppression after the administration of free stibogluconate.

M Collins1, K C Carter, A J Baillie.   

Abstract

BALB/c mice with an acute or chronic Leishmania donovani infection were treated with intravenous sodium stibogluconate solution and the parasite suppressions determined in the spleen, liver and femur bone marrow. Antimony concentrations in these and other tissues were determined by hydride generation-atomic absorption spectrophotometry. There was little correlation between tissue antimony levels one hour after treatment and drug efficacy. It would appear that the peak tissue antimony concentration achieved soon after dosing, rather than the lower concentrations which are readily sustained in most tissues, is the most important factor in the antileishmanial activity of stibogluconate. A high peak antimony concentration occurred in the liver, where parasites were significantly suppressed, and was not observed in the two other sites of infection, where the parasites were apparently less susceptible to stibogluconate therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1319700     DOI: 10.1080/00034983.1992.11812628

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  7 in total

1.  Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum.

Authors:  J P Gangneux; M Dullin; A Sulahian; Y J Garin; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

2.  Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome.

Authors:  J P Gangneux; A Sulahian; Y J Garin; R Farinotti; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

3.  Skin uptake, distribution, and elimination of antimony following administration of sodium stibogluconate to patients with cutaneous leishmaniasis.

Authors:  M al Jaser; A el-Yazigi; M Kojan; S L Croft
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

4.  Combination therapy using sodium antimony gluconate in stearylamine-bearing liposomes against established and chronic Leishmania donovani infection in BALB/c Mice.

Authors:  Swati Pal; Rajesh Ravindran; Nahid Ali
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

5.  In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species.

Authors:  Louis Maes; Dirk Vanden Berghe; Nils Germonprez; Ludo Quirijnen; Paul Cos; Norbert De Kimpe; Luc Van Puyvelde
Journal:  Antimicrob Agents Chemother       Date:  2004-01       Impact factor: 5.191

6.  Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice.

Authors:  Samanta Etel Treiger Borborema; João Alberto Osso; Heitor Franco de Andrade; Nanci do Nascimento
Journal:  Mem Inst Oswaldo Cruz       Date:  2013-08       Impact factor: 2.743

7.  Accelerated Blood Clearance (ABC) Phenomenon Favors the Accumulation of Tartar Emetic in Pegylated Liposomes in BALB/c Mice Liver.

Authors:  Tamara C M Lopes; Débora F Silva; Walyson C Costa; Frédéric Frézard; José M Barichello; Neila M Silva-Barcellos; Wanderson G de Lima; Simone A Rezende
Journal:  Patholog Res Int       Date:  2018-01-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.